ProQR Therapeutics
PRQR | NASDAQ
$1.18
-$0.23 (-16.31%)
At close: Nov 16, 2026, 4:00 PM ET
$1.23
+$0.05 (+4.24%)
After-hours:
Nov 16, 2026, 7:30 PM ET
ProQR Therapeutics Company Profile
Company profile explainedCompany Profile
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
Key Executives
| Name | Position |
|---|---|
| Daniel Anton de Boer | Founder, CEO & Executive Director |
| Dennis Hom | Chief Financial Officer |
| Christopher Hart | Chief Data & AI Officer |
| Cristina Lopez Lopez | Chief Medical Officer |
| Gerard Platenburg | Co-Founder, Chief Scientific Officer & Executive Director |
| Golnar Karimian | Head of Hepatology |
| Sandra van der Kolk | Junior Financial Controller |
| Sarah Cue Kiely | Vice President of Investor Relations & Corporate Communications |
| Sheila Sponselee | Chief People & Operations Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | 6-K/A | [Amend] Filing |
| Oct 28, 2026 | 6-K | Filing |
| Sep 23, 2026 | 6-K | Filing |
| Sep 09, 2026 | 6-K | Filing |
| Aug 13, 2026 | 6-K | Filing |
| Aug 13, 2026 | 6-K | Filing |
| Aug 03, 2026 | 4 | Filing |
| Jul 29, 2026 | SC 13D/A | [Amend] Filing |
| Jul 29, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jul 24, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
ProQR Therapeutics
| Country | Netherlands |
| IPO Date | Sep 18, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 166 |
| CEO | Daniel Anton de Boer |
Stock Details
| Ticker Symbol | PRQR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001612940 |
| CUSIP Number | N71542109 |
| ISIN Number | NL0010872495 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove PRQR